Liminatus Pharma Regains Compliance With Nasdaq Minimum Bid Price Rule
Liminatus Pharma announced it has regained compliance with Nasdaq's minimum bid price rule after its stock price rose above $1.00 per share for 13 consecutive trading days. The biotechnology company avoided delisting following a reverse stock split and a Nasdaq hearing.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed